Work

Clinical Treatment Decisions for Advanced Renal Cell Cancer

Year: 2013

Type: article

Abstract: Seven targeted agents have improved the prognosis of advanced renal cell carcinoma (RCC), but none are effective in the post-nephrectomy adjuvant setting. Among the available first-line options for advanced RCC, sunitinib remains the most commonly used first-line therapy, but several studies suggest pazopanib may be better tolerated. Increasingly, choice of therapy may be driven by toxicity profiles. Cytoreductive nephrectomy remains important, even in the era of targeted therapies in selected patients.

Source: Journal of the National Comprehensive Cancer Network

DOI: 10.6004/jnccn.2013.0204

Author: Toni K. Choueiri

Institutions: Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W1894487057